http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 06:02:04 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Natera%27s+Signatera+outperforms+AMERK+in+skin+cancer+recurrence+study/26797488.html <p>Natera, Inc. (NASDAQ: NTRA) announced the publication of a study in <em>JAMA Dermatology</em> comparing its Signatera test against the Merkel cell polyomavirus antibody test, known as AMERK, for monitoring recurrence of Merkel cell carcinoma (MCC), a rare skin cancer that recurs in approximately 40% of patients.</p><p>The retrospective analysis of a prospective, multicenter study included 169 MCC patients. Key findings showed Signatera demonstrated a sensitivity of 90% compared to 55% for AMERK. Signatera also showed a higher positive predictive value, higher negative predictive value, and a hazard ratio difference of 6.6 (p < 0.001) over AMERK. In patients where both tests http://www.streetinsider.com/Corporate+News/Natera%27s+Signatera+outperforms+AMERK+in+skin+cancer+recurrence+study/26797488.html Wed, 22 Jul 2026 06:02:04 -0400 NTRA http://www.streetinsider.com/FDA/Natera%27s+Signatera+outperforms+AMERK+in+skin+cancer+recurrence+study/26797488.html <p>Natera, Inc. (NASDAQ: NTRA) announced the publication of a study in <em>JAMA Dermatology</em> comparing its Signatera test against the Merkel cell polyomavirus antibody test, known as AMERK, for monitoring recurrence of Merkel cell carcinoma (MCC), a rare skin cancer that recurs in approximately 40% of patients.</p><p>The retrospective analysis of a prospective, multicenter study included 169 MCC patients. Key findings showed Signatera demonstrated a sensitivity of 90% compared to 55% for AMERK. Signatera also showed a higher positive predictive value, higher negative predictive value, and a hazard ratio difference of 6.6 (p < 0.001) over AMERK. In patients where both tests http://www.streetinsider.com/FDA/Natera%27s+Signatera+outperforms+AMERK+in+skin+cancer+recurrence+study/26797488.html Wed, 22 Jul 2026 06:02:04 -0400 NTRA http://www.streetinsider.com/Press+Releases/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html <p class="bwalignc"><i>Signatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrence</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=e9fcfbef976ae6a1bf36f0e538a15bff" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamadermatology%2Ffullarticle%2F2851488%3FguestAccessKey%3D15e25352-a25b-44da-b05b-136e59b6c6e1%26utm_medium%3Demail%26utm_source%3Dpostup_jn%26utm_campaign%3Darticle_alert-jamadermatology%26utm_content%3Dolf-tfl_%26utm_term%3D070826&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=published&amp;index=2&amp;md5=9a294e0f057b97501859347c2c209daa" shape="rect">published</a> in <i>JAMA Dermatology</i>. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected http://www.streetinsider.com/Press+Releases/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html Wed, 22 Jul 2026 06:00:00 -0400 A.11955935 NTRA O.05077750 O.21533112 http://www.streetinsider.com/Press+Releases/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html <p class="bwalignc"><i>Signatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrence</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=e9fcfbef976ae6a1bf36f0e538a15bff" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamadermatology%2Ffullarticle%2F2851488%3FguestAccessKey%3D15e25352-a25b-44da-b05b-136e59b6c6e1%26utm_medium%3Demail%26utm_source%3Dpostup_jn%26utm_campaign%3Darticle_alert-jamadermatology%26utm_content%3Dolf-tfl_%26utm_term%3D070826&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=published&amp;index=2&amp;md5=9a294e0f057b97501859347c2c209daa" shape="rect">published</a> in <i>JAMA Dermatology</i>. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected http://www.streetinsider.com/Press+Releases/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html Wed, 22 Jul 2026 06:00:00 -0400 A.11955935 NTRA O.05077750 O.21533112 http://www.streetinsider.com/Press+Releases/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html <p class="bwalignc"><i>Signatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrence</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=e9fcfbef976ae6a1bf36f0e538a15bff" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamadermatology%2Ffullarticle%2F2851488%3FguestAccessKey%3D15e25352-a25b-44da-b05b-136e59b6c6e1%26utm_medium%3Demail%26utm_source%3Dpostup_jn%26utm_campaign%3Darticle_alert-jamadermatology%26utm_content%3Dolf-tfl_%26utm_term%3D070826&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=published&amp;index=2&amp;md5=9a294e0f057b97501859347c2c209daa" shape="rect">published</a> in <i>JAMA Dermatology</i>. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected http://www.streetinsider.com/Press+Releases/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html Wed, 22 Jul 2026 06:00:00 -0400 A.11955935 NTRA O.05077750 O.21533112 http://www.streetinsider.com/Press+Releases/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html <p class="bwalignc"><i>Signatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrence</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=e9fcfbef976ae6a1bf36f0e538a15bff" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamadermatology%2Ffullarticle%2F2851488%3FguestAccessKey%3D15e25352-a25b-44da-b05b-136e59b6c6e1%26utm_medium%3Demail%26utm_source%3Dpostup_jn%26utm_campaign%3Darticle_alert-jamadermatology%26utm_content%3Dolf-tfl_%26utm_term%3D070826&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=published&amp;index=2&amp;md5=9a294e0f057b97501859347c2c209daa" shape="rect">published</a> in <i>JAMA Dermatology</i>. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected http://www.streetinsider.com/Press+Releases/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html Wed, 22 Jul 2026 06:00:00 -0400 A.11955935 NTRA O.05077750 O.21533112 http://www.streetinsider.com/Business+Wire/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html <p class="bwalignc"><i>Signatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrence</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=e9fcfbef976ae6a1bf36f0e538a15bff" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamadermatology%2Ffullarticle%2F2851488%3FguestAccessKey%3D15e25352-a25b-44da-b05b-136e59b6c6e1%26utm_medium%3Demail%26utm_source%3Dpostup_jn%26utm_campaign%3Darticle_alert-jamadermatology%26utm_content%3Dolf-tfl_%26utm_term%3D070826&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=published&amp;index=2&amp;md5=9a294e0f057b97501859347c2c209daa" shape="rect">published</a> in <i>JAMA Dermatology</i>. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected http://www.streetinsider.com/Business+Wire/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html Wed, 22 Jul 2026 06:00:00 -0400 A.11955935 NTRA O.05077750 O.21533112 http://www.streetinsider.com/Business+Wire/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html <p class="bwalignc"><i>Signatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrence</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=e9fcfbef976ae6a1bf36f0e538a15bff" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamadermatology%2Ffullarticle%2F2851488%3FguestAccessKey%3D15e25352-a25b-44da-b05b-136e59b6c6e1%26utm_medium%3Demail%26utm_source%3Dpostup_jn%26utm_campaign%3Darticle_alert-jamadermatology%26utm_content%3Dolf-tfl_%26utm_term%3D070826&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=published&amp;index=2&amp;md5=9a294e0f057b97501859347c2c209daa" shape="rect">published</a> in <i>JAMA Dermatology</i>. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected http://www.streetinsider.com/Business+Wire/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html Wed, 22 Jul 2026 06:00:00 -0400 A.11955935 NTRA O.05077750 O.21533112 http://www.streetinsider.com/Business+Wire/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html <p class="bwalignc"><i>Signatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrence</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=e9fcfbef976ae6a1bf36f0e538a15bff" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamadermatology%2Ffullarticle%2F2851488%3FguestAccessKey%3D15e25352-a25b-44da-b05b-136e59b6c6e1%26utm_medium%3Demail%26utm_source%3Dpostup_jn%26utm_campaign%3Darticle_alert-jamadermatology%26utm_content%3Dolf-tfl_%26utm_term%3D070826&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=published&amp;index=2&amp;md5=9a294e0f057b97501859347c2c209daa" shape="rect">published</a> in <i>JAMA Dermatology</i>. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected http://www.streetinsider.com/Business+Wire/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html Wed, 22 Jul 2026 06:00:00 -0400 A.11955935 NTRA O.05077750 O.21533112 http://www.streetinsider.com/Business+Wire/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html <p class="bwalignc"><i>Signatera outperformed AMERK, the current standard of care for prognosis and recurrence monitoring, across sensitivity, positive and negative predictive value, and lead time to recurrence</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=e9fcfbef976ae6a1bf36f0e538a15bff" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjamadermatology%2Ffullarticle%2F2851488%3FguestAccessKey%3D15e25352-a25b-44da-b05b-136e59b6c6e1%26utm_medium%3Demail%26utm_source%3Dpostup_jn%26utm_campaign%3Darticle_alert-jamadermatology%26utm_content%3Dolf-tfl_%26utm_term%3D070826&amp;esheet=54574820&amp;newsitemid=20260722520063&amp;lan=en-US&amp;anchor=published&amp;index=2&amp;md5=9a294e0f057b97501859347c2c209daa" shape="rect">published</a> in <i>JAMA Dermatology</i>. The study evaluated the Signatera test against the Merkel cell polyomavirus antibody test (AMERK), finding Signatera to be a significantly stronger predictor of recurrence that also detected http://www.streetinsider.com/Business+Wire/Signatera%E2%84%A2+MRD+Outperformed+AMERK+Testing+in+Predicting+Merkel+Cell+Carcinoma+Recurrence+in+JAMA+Dermatology+Study/26797380.html Wed, 22 Jul 2026 06:00:00 -0400 A.11955935 NTRA O.05077750 O.21533112 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+15++Filed+by%3A+Sheena+Jonathan/26785509.html si-local-file:///var/storage/secattach/20260717/26785509.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+15++Filed+by%3A+Sheena+Jonathan/26785509.html Fri, 17 Jul 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+15++Filed+by%3A+Sheena+Jonathan/26785509.html si-local-file:///var/storage/secattach/20260717/26785509.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+15++Filed+by%3A+Sheena+Jonathan/26785509.html Fri, 17 Jul 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+15++Filed+by%3A+Chapman+Rowan+E/26785510.html si-local-file:///var/storage/secattach/20260717/26785510.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+15++Filed+by%3A+Chapman+Rowan+E/26785510.html Fri, 17 Jul 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+15++Filed+by%3A+Chapman+Rowan+E/26785510.html si-local-file:///var/storage/secattach/20260717/26785510.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+15++Filed+by%3A+Chapman+Rowan+E/26785510.html Fri, 17 Jul 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/Press+Releases/Finalized+MolDx+LCD+Includes+Expanded+Coverage+for+Natera%E2%80%99s+Prospera%E2%84%A2+Portfolio/26780838.html <p class="bwalignc"><i>Surveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settings</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54572158&amp;newsitemid=20260716661899&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=cb599037709525a7bf5276365f957cfb" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.</p><p>The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes:</p><ul class="bwlistdisc"><li><b>Kidney</b>: 6 tests in year 1; 4 per year in http://www.streetinsider.com/Press+Releases/Finalized+MolDx+LCD+Includes+Expanded+Coverage+for+Natera%E2%80%99s+Prospera%E2%84%A2+Portfolio/26780838.html Thu, 16 Jul 2026 18:35:00 -0400 NTRA O.05077750 http://www.streetinsider.com/Press+Releases/Finalized+MolDx+LCD+Includes+Expanded+Coverage+for+Natera%E2%80%99s+Prospera%E2%84%A2+Portfolio/26780838.html <p class="bwalignc"><i>Surveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settings</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54572158&amp;newsitemid=20260716661899&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=cb599037709525a7bf5276365f957cfb" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.</p><p>The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes:</p><ul class="bwlistdisc"><li><b>Kidney</b>: 6 tests in year 1; 4 per year in http://www.streetinsider.com/Press+Releases/Finalized+MolDx+LCD+Includes+Expanded+Coverage+for+Natera%E2%80%99s+Prospera%E2%84%A2+Portfolio/26780838.html Thu, 16 Jul 2026 18:35:00 -0400 NTRA O.05077750 http://www.streetinsider.com/Business+Wire/Finalized+MolDx+LCD+Includes+Expanded+Coverage+for+Natera%E2%80%99s+Prospera%E2%84%A2+Portfolio/26780838.html <p class="bwalignc"><i>Surveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settings</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54572158&amp;newsitemid=20260716661899&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=cb599037709525a7bf5276365f957cfb" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.</p><p>The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes:</p><ul class="bwlistdisc"><li><b>Kidney</b>: 6 tests in year 1; 4 per year in http://www.streetinsider.com/Business+Wire/Finalized+MolDx+LCD+Includes+Expanded+Coverage+for+Natera%E2%80%99s+Prospera%E2%84%A2+Portfolio/26780838.html Thu, 16 Jul 2026 18:35:00 -0400 NTRA O.05077750 http://www.streetinsider.com/Business+Wire/Finalized+MolDx+LCD+Includes+Expanded+Coverage+for+Natera%E2%80%99s+Prospera%E2%84%A2+Portfolio/26780838.html <p class="bwalignc"><i>Surveillance coverage significantly strengthened with new LCD across kidney, heart, and lung transplantation, expanding coverage for Prospera testing across critical post-transplant settings</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54572158&amp;newsitemid=20260716661899&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=cb599037709525a7bf5276365f957cfb" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.</p><p>The LCD strengthens coverage for Prospera in the surveillance settings. The new policy, which is expected to take effect on August 30, 2026, specifically includes:</p><ul class="bwlistdisc"><li><b>Kidney</b>: 6 tests in year 1; 4 per year in http://www.streetinsider.com/Business+Wire/Finalized+MolDx+LCD+Includes+Expanded+Coverage+for+Natera%E2%80%99s+Prospera%E2%84%A2+Portfolio/26780838.html Thu, 16 Jul 2026 18:35:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+13++Filed+by%3A+Sheena+Jonathan/26775268.html si-local-file:///var/storage/secattach/20260715/26775268.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+13++Filed+by%3A+Sheena+Jonathan/26775268.html Wed, 15 Jul 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+13++Filed+by%3A+Sheena+Jonathan/26775268.html si-local-file:///var/storage/secattach/20260715/26775268.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jul+13++Filed+by%3A+Sheena+Jonathan/26775268.html Wed, 15 Jul 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Natera%2C+Inc.+++++++++++++++++++++++++++Filed+by%3A+Chapman+Rowan+E/26774269.html si-local-file:///var/storage/secattach/20260715/26774269.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Natera%2C+Inc.+++++++++++++++++++++++++++Filed+by%3A+Chapman+Rowan+E/26774269.html Wed, 15 Jul 2026 16:13:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Natera%2C+Inc.+++++++++++++++++++++++++++Filed+by%3A+Chapman+Rowan+E/26774269.html si-local-file:///var/storage/secattach/20260715/26774269.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Natera%2C+Inc.+++++++++++++++++++++++++++Filed+by%3A+Chapman+Rowan+E/26774269.html Wed, 15 Jul 2026 16:13:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Natera%2C+Inc.+++++++++++++++++++++++++++Filed+by%3A+Sheena+Jonathan/26772390.html si-local-file:///var/storage/secattach/20260715/26772390.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Natera%2C+Inc.+++++++++++++++++++++++++++Filed+by%3A+Sheena+Jonathan/26772390.html Wed, 15 Jul 2026 10:11:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Natera%2C+Inc.+++++++++++++++++++++++++++Filed+by%3A+Sheena+Jonathan/26772390.html si-local-file:///var/storage/secattach/20260715/26772390.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Natera%2C+Inc.+++++++++++++++++++++++++++Filed+by%3A+Sheena+Jonathan/26772390.html Wed, 15 Jul 2026 10:11:00 -0400 NTRA O.05077750 http://www.streetinsider.com/Analyst+PT+Change/Natera+%28NTRA%29+PT+Raised+to+%24330+at+Canaccord/26764499.html Canaccord analyst Kyle Mikson raised the price target on Natera (NASDAQ: NTRA) to $330.00 (from $285.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Natera+%28NTRA%29+PT+Raised+to+%24330+at+Canaccord/26764499.html Tue, 14 Jul 2026 06:42:28 -0400 NTRA